Recent Updates
Recently added Catalysts
BCRX Positive Sentiment Score: 75/100

BioCryst to Present at Upcoming Investor Conferences

Key Takeaway: BioCryst Pharmaceuticals announced its participation in two upcoming investor conferences. The Bank of America Health Care Conference will take place on May 12, 2026, followed by the Jefferies Global Healthcare Conference on June 3, 2026. These events will allow the company to present its advancements in rare disease treatments.

Conference Participation Details

Jefferies Global Healthcare Conference
Date: November 18, 2025
Time: 11:30 a.m. GMT / 6:30 a.m. ET
Location: London
Format: Fireside Chat

How to Access

Investors and the general public can listen to both sessions live at:

https://investor.viatris.com

Archived versions will be available following the live events for a limited time.

Market Sentiment Analysis

POSITIVE FACTORS

  • BioCryst is actively engaging with investors through presentations.
  • The company is showcasing its commitment to rare disease treatment.
  • Upcoming conferences provide a platform for sharing advancements.

Full Press Release Details

RESEARCH TRIANGLE PARK, N.C., April 28, 2026 (GLOBE NEWSWIRE) --BioCryst Pharmaceuticals, Inc.(Nasdaq: BCRX) today announced that the company plans to present at the following conferences:
• Bank of America Health Care Conference in Las Vegas on Tuesday, May 12, 2026, at 4:40 p.m. ET.
• Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026, at 3:45 p.m. ET.
Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst’s website atwww.biocryst.com.

About BioCryst Pharmaceuticals

BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO®(berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics for a range of rare diseases. For more information, please visitwww.biocryst.comor follow us onLinkedIn.
BCRXW

Contact:

Frequently Asked Questions

When is BioCryst presenting at the Bank of America Conference?

BioCryst will present at the Bank of America Health Care Conference on May 12, 2026.

Where can I access the presentations from BioCryst?

The live audio webcasts and replays can be accessed on BioCryst's website.

What is BioCryst's focus in the biopharma industry?

BioCryst focuses on developing medicines for hereditary angioedema and other rare diseases.

What is ORLADEYO?

ORLADEYO is the first oral, once-daily plasma kallikrein inhibitor commercialized by BioCryst.

Last updated: Apr 28, 2026